Patient with prostatic adenocarcinoma with plasmacytoid features and an aberrant immunohistochemical phenotype diagnosed by biopsy and a mini‑review of plasmacytoid features in the genitourinary system: A case report

Zacharouli,Konstantina; Vageli,Dimitra P.; Koukoulis,George K.; Ioannou,Maria

doi:10.3892/mco.2022.2500

Patient with prostatic adenocarcinoma with plasmacytoid features and an aberrant immunohistochemical phenotype diagnosed by biopsy and a mini‑review of plasmacytoid features in the genitourinary system: A case report

Authors:
- Konstantina Zacharouli
- Dimitra P. Vageli
- George K. Koukoulis
- Maria Ioannou
View Affiliations

Affiliations: Department of Pathology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, 41500 Larissa, Greece
Published online on: January 20, 2022 https://doi.org/10.3892/mco.2022.2500
Article Number: 67

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer is one of the most commonly diagnosed malignancies in men. Most of these tumors are adenocarcinomas. Plasmacytoid is a rare variant of adenocarcinoma described by previous studies in the genitourinary system and is characterized by the plasmacytoid appearance of tumor cells with abundant cytoplasm and abnormally placed hyperchromatic nuclei. However, to the best of our knowledge, plasmacytoid adenocarcinoma has rarely been described in the prostate. This report describes a new case of plasmacytoid adenocarcinoma of the prostate diagnosed by biopsy and summarizes the known literature on plasmacytoid features in the genitourinary system. A 62‑year‑old male patient presented to the hospital with urinary retention, hematuria, weakness and weight loss. The digital rectal examination revealed an irregular enlargement. Laboratory findings showed elevated levels of prostate specific antigen (PSA; 43.6 ng/ml). Transrectal ultrasound showed invasion of the right seminal vesicle. Prostate tumor core biopsies were collected and sent for diagnosis. Histological examination revealed a high‑grade prostatic adenocarcinoma Gleason score of 5+5 (total score 10). The tumor cells had a plasmacytoid appearance with abundant cytoplasm and abnormally placed hyperchromatic nuclei. The immunohistochemical phenotype was characterized by abundant positivity for cytokeratin (CK)AE1/AE3 and PSA. By contrast, tumor cells were negative for p63, CK 34BE12 and GATA binding protein 3 (urothelial markers), synaptophysin (neuroendocrine marker). Tumor cells were also negative for E‑cadherin, which is particularly indicative of CDH1 alterations. To the best of our knowledge, this is the first description of a plasmacytoid adenocarcinoma of the prostate diagnosed by biopsy, showing an irregular immunophenotype that may indicate somatic CDH1 alterations. The presentation of a novel rare variant of prostatic carcinoma that differs from other neoplasms of the genitourinary system may contribute to an improved understanding of this uncommonly found histological pattern that may also be mandatory due to the clinical and prognostic implications of this diagnosis.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
2	Baade PD, Youlden DR and Krnjacki LJ: International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol Nutr Food Res. 53:171–184. 2009.PubMed/NCBI View Article : Google Scholar
3	Humphrey PA: Histopathology of prostate cancer. Cold Spring Harb Perspect Med. 7(a030411)2017.PubMed/NCBI View Article : Google Scholar
4	Kweldam CF, van Leenders GJ and van der Kwast T: Grading of prostate cancer: A work in progress. Histopathology. 74:146–160. 2019.PubMed/NCBI View Article : Google Scholar
5	Lopez-Beltran A, Requena MJ, Montironi R, Blanca A and Cheng L: Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol. 40:1023–1028. 2009.PubMed/NCBI View Article : Google Scholar
6	Fox MD, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Zhang L, Dinney CP, Czerniak B and Guo CC: Plasmacytoid urothelial carcinoma of the urinary bladder: A clinicopathologic and immunohistochemical analysis of 49 cases. Am J Clin Pathol. 147:500–506. 2017.PubMed/NCBI View Article : Google Scholar
7	Cockerill PA, Cheville JC, Boorjian SA, Blackburne A, Thapa P, Tarrell RF and Frank I: Outcomes following radical cystectomy for plasmacytoid urothelial carcinoma: Defining the need for improved local cancer control. Urology. 102:143–147. 2017.PubMed/NCBI View Article : Google Scholar
8	Al-Hussain T, Haffner MC, Altaweel WM and Epstein JI: Plasmacytoid acinar adenocarcinoma of the prostate: A newly described variant of prostate cancer. Hum Pathol. 94:86–91. 2019.PubMed/NCBI View Article : Google Scholar
9	Nguyen JK, Chen YY, Magi-Galluzzi C and McKenney JK: Clinicopathological study of Gleason pattern 5 prostatic adenocarcinoma with ‘single-cell’ growth reveal 2 distinct types, one with ‘plasmacytoid ‘features. Am J Pathol. 44:1635–1642. 2020.PubMed/NCBI View Article : Google Scholar
10	Li Q, Assel M, Benfante NE, Pietzak EJ, Herr HW, Donat M, Cha EK, Donahue TF, Bochner BH and Dalbagni G: The impact of plasmacytoid variant histology on the survival of patients with urothelial carcinoma of bladder after radical cystectomy. Eur Urol Focus. 5:104–108. 2019.PubMed/NCBI View Article : Google Scholar
11	Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP and Siefker-Radtke AO: Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 189:1656–1661. 2013.PubMed/NCBI View Article : Google Scholar
12	Ericson KJ, Thomas L and Lee BH: Plasmacytoid variant urothelial carcinoma: Clinicopathologic outcomes and experience with neoadjuvant chemotherapy. J Clin Oncol. 37(483)2019.
13	Diamantopoulos LN, Khaki AR, Vakar-Lopez F, Tretiakova MS, Gore JL, Schade GR, Psutka SP, Hsieh AC, Lee JK, Hsieh AC, et al: Patient (pt) characteristics, treatment patterns, outcomes and prognostic factors in plasmacytoid urothelial carcinoma (PUC). J Clin Oncol. 37 (Suppl 15):e16007. 2019.
14	Straccia P, Martini M, Sacco E, Bassi PF and Pierconti F: Cytological features of micropapillary and plasmacytoid variants of urothelial carcinoma. Diagn Cytopathol. 48:111–117. 2020.PubMed/NCBI View Article : Google Scholar
15	Jibril A and Steven AC: Plasmacytoid urothelial carcinoma of ureter with retroperitoneal metastasis: A case report. Am J Case Rep. 19:158–162. 2018.PubMed/NCBI View Article : Google Scholar
16	Takada-Owada A, Nozawa Y, Onozaki M, Noda S, Jamiyan T, Tokura Y, Nakazato Y, Kamai T and Ishida K: Plasmacytoid urothelial carcinoma of renal pelvis with positive zinc finger E-box-binding homeobox 1: A case report. Diagn Pathol. 15(124)2020.PubMed/NCBI View Article : Google Scholar
17	Keck B, Wach S, Kunath F, Bertz S, Taubert H, Lehmann J, Stöckle M, Wullich B and Hartmann A: Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladder. Ann Surg Oncol. 20:2440–2445. 2013.PubMed/NCBI View Article : Google Scholar
18	Lim MG, Adsay NV, Grignon DJ and Osunkoya AO: E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: Comparison with usual-type high-grade urothelial carcinoma. Mod Pathol. 24:241–247. 2011.PubMed/NCBI View Article : Google Scholar
19	Ma B, Khazali A, Shao H, Jiang Y and Wells A: Expression of E-cadherin and specific CXCR3 isoforms impact each other in prostate cancer. Cell Commun Signal. 17(164)2019.PubMed/NCBI View Article : Google Scholar
20	Sangoi AR, Chan E, Stohr BA and Kunju LP: Invasive plasmacytoid urothelial carcinoma: A comparative study of E-cadherin and P120 catenin. Hum Pathol. 102:54–59. 2020.PubMed/NCBI View Article : Google Scholar
21	Palsgrove DN, Taheri D, Springer SU, Cowan M, Guner G, Rodriguez MA, Pena MDC, Wang Y, Kinde I, Ricardo BFP, et al: Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Hum Pathol. 85:1–9. 2019.PubMed/NCBI View Article : Google Scholar
22	Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, et al: Prostate cancer version 2.2019, NCCN clinical practise guidelines in oncology. J Natl Compr Canc Netw. 17:479–505. 2019.PubMed/NCBI View Article : Google Scholar
23	Nelson RS and Epstein JI: 1996. Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Am J Surg Pathol. 20:419–426. 1996.PubMed/NCBI View Article : Google Scholar
24	Cina SJ and Epstein JI: Adenocarcinoma of the prostate with atrophic feature. Am J Surg Pathol. 21:289–295. 1997.PubMed/NCBI View Article : Google Scholar
25	Humphrey PA, Kaleem Z, Swanson PE and Vollmer RT: Pseudohyperplastic prostatic adenocarcinoma. Am J Surg Pathol. 22:1239–1246. 1998.PubMed/NCBI View Article : Google Scholar
26	Wolf AN and Epstein JI: Pseudohyperplastic prostatic adenocarcinoma in needle biopsy and simple prostatectomy. Am J Surg Pathol. 24:1039–1046. 2000.PubMed/NCBI View Article : Google Scholar
27	Yaskiv O, Cao D and Humphrey PA: Microcystic adenocarcinoma of the prostate: A variant of pseudohyperplastic and atrophic patterns. Am J Surg Pathol. 34:556–561. 2010.PubMed/NCBI View Article : Google Scholar
28	Levi AW and Epstein JI: Pseudohyperplastic prostatic adenocarcinoma in needle biopsy and simple prostatectomy. Am J Surg Pathol. 24:1039–1046. 2000.PubMed/NCBI View Article : Google Scholar
29	Lopez-Beltran A, Eble JN and Bostwick DG: Pleomorphic giant cell carcinoma of the prostate. Arch Pathol Lab Med. 129:683–685. 2005.PubMed/NCBI View Article : Google Scholar
30	Parwani AV, Herawi M and Epstein JI: Pleomorphic giant cell adenocarcinoma of the prostate: Report of 6 cases. Am J Surg Pathol. 30:1254–1259. 2006.PubMed/NCBI View Article : Google Scholar
31	Hansel DE and Epstein JI: Sarcomatoid carcinoma of the prostate: A study of 42 cases. Am J Surg Pathol. 30:1316–1321. 2006.PubMed/NCBI View Article : Google Scholar
32	Epstein JI, Amin MB, Reuter VE and Humphrey PA: Contemporary gleason grading of prostatic carcinoma: An update with discussion of practical issues to implement the 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol. 41:e1–e7. 2017.PubMed/NCBI View Article : Google Scholar
33	Humphrey PA: Variants of acinar adenocarcinoma of the prostate mimicking benign conditions. Mod Pathol. 31 (S1):S64–S70. 2018.PubMed/NCBI View Article : Google Scholar
34	Gottipati S, Warncke J, Vollmer R and Humphrey PA: Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue. Am J Surg Pathol. 36:900–907. 2012.PubMed/NCBI View Article : Google Scholar
35	Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR and Humphrey PA: Grading Committee. The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 40:244–252. 2016.PubMed/NCBI View Article : Google Scholar
36	Al-Ahmadie HA, Iyer G, Lee BH, Scott SN, Mehra R, Bagrodia A, Jordan EJ, Gao SP, Ramirez R, Cha EK, et al: Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat Genet. 48:356–358. 2016.PubMed/NCBI View Article : Google Scholar
37	Schrader KA, Masciari S, Boyd N, Wiyrick S, Kaurah P, Senz J, Burke W, Lynch HT, Garber JE and Huntsman DG: Hereditary diffuse gastric cancer: Association with lobular breast cancer. Fam Cancer. 7:73–82. 2008.PubMed/NCBI View Article : Google Scholar
38	Oliveira C, Senz J, Kaurah P, Pinheiro H, Sanges R, Haegert A, Corso G, Schouten J, Fitzgerald R, Vogelsang H, et al: Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet. 18:1545–1555. 2009.PubMed/NCBI View Article : Google Scholar
39	Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, Grundei T, Becker KF, Mueller J, Siewert JR and Höfler H: Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 155:337–342. 1999.PubMed/NCBI View Article : Google Scholar
40	Sahin AA, Myhre M, Ro JY, Sneige N, Dekmezian RH and Ayala AG: Plasmacytoid transitional cell carcinoma. Report of a case with initial presentation mimicking multiple myeloma. Acta Cytol. 35:277–280. 1991.PubMed/NCBI
41	Coyne JD and Sim E: Urothelial neoplasia with plasmacytoid morphology. Histopathology. 48:200–201. 2006.PubMed/NCBI View Article : Google Scholar
42	Wang YG, Perera M and Gleeson J: Plasmacytoid urothelial carcinoma of the bladder with extensive scrotal wall invasion. Urol Ann. 8:381–383. 2016.PubMed/NCBI View Article : Google Scholar
43	Fritsche HM, Burger M, Denzinger S, Legal W, Goebell PJ and Hartmann A: Plasmacytoid urothelial carcinoma of the bladder: Histological and clinical features of 5 cases. J Urol. 180:1923–1927. 2008.PubMed/NCBI View Article : Google Scholar
44	Bougen NM, Amiry N, Yuan Y, Kong XJ, Pandey V, Vidal LJ, Perry JK, Zhu T and Lobie PE: Trefoil factor 1 suppression of E-CADHERIN enhances prostate carcinoma cell invasiveness and metastasis. Cancer Lett. 332:19–29. 2013.PubMed/NCBI View Article : Google Scholar
45	Nauseef JT and Henry MD: Epithelial-to-mesenchymal transition in prostate cancer: Paradigm or puzzle? Nat Rev Urol. 8:428–439. 2011.PubMed/NCBI View Article : Google Scholar
46	Lee HM, Hwang KA and Choi KC: Diverse pathways of epithelial mesenchymal transition related with cancer progression and metastasis and potential effects of endocrine disrupting chemicals on epithelial mesenchymal transition process. Mol Cell Endocrinol. 457:103–113. 2017.PubMed/NCBI View Article : Google Scholar
47	Chunthapong J, Seftor EA, Khalkhali-Ellis Z, Seftor RE, Amir S, Lubaroff DM, Heidger PM Jr and Hendrix MJ: Dual roles of E-cadherin in prostate cancer invasion. J Cell Biochem. 91:649–661. 2004.PubMed/NCBI View Article : Google Scholar
48	Epstein JI: Prostate cancer grading: A contemporary photomontage. Am J Surg Pathol. 40(137)2016.PubMed/NCBI View Article : Google Scholar
49	Epstein JI, Egevad L, Humphrey PA and Montironi R: Members of the ISUP Immunohistochemistry In Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the prostate: Report from the international society of urologic pathology consensus conference. Am J Surg Pathol. 38:e6–e19. 2014.PubMed/NCBI View Article : Google Scholar
50	Dehm SM and Tindall DJ: Molecular regulation of androgen action in prostate cancer. J Cell Biochem. 99:333–344. 2006.PubMed/NCBI View Article : Google Scholar
51	Zhang X, Zhang Z, Chen S, Jiang J, Qi R, Mi X, Zhang X, Xi Y, Zheng H and Hua B: Prognostic significance of E-cadherin expression in prostatic carcinoma: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 99(e19707)2020.PubMed/NCBI View Article : Google Scholar